BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SIF001 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SIF001\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07051629-8904@assetmemo.bio
DTSTAMP:20261121T005849Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:SIF001: Phase 1 readout est. (NCT07051629)
DESCRIPTION:SIF001\, phase 1\, Epilepsy.\nStudy: Dose Escalation Study to A
 ssess the Safety\, Tolerability\, Pharmacokinetics And Pharmacodynamics of
  SIF001 in Healthy Subjects and in Epilepsy Patients\nEstimated primary co
 mpletion: 15 January 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/sif001#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07051629
URL:https://assetmemo.bio/drug/sif001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
